Atara Biotherapeutics Discloses 23% Workforce Reduction in Q3 Filing as Pierre Fabre Advances Ebvallo BLA Review
Allogeneic cell therapy developer Atara Biotherapeutics disclosed in its Q3 Form 10-Q that it eliminated 23% of its workforce to leave roughly 10 staff and manage a $9.9 million cash position while partner Pierre Fabre awaits a March 2027 FDA decision for Ebvallo.